169 related articles for article (PubMed ID: 35982823)
21. Design and Syntheses of Anti-Tuberculosis Agents Inspired by BTZ043 Using a Scaffold Simplification Strategy.
Tiwari R; Möllmann U; Cho S; Franzblau SG; Miller PA; Miller MJ
ACS Med Chem Lett; 2014 May; 5(5):587-91. PubMed ID: 24900885
[TBL] [Abstract][Full Text] [Related]
22. Design and synthesis of benzofuran- and naphthalene-fused thiazinones as antimycobacterial agents.
Keiff F; Jacques Dit Lapierre TJW; Bernal FA; Kloss F
Arch Pharm (Weinheim); 2023 Nov; 356(11):e2300356. PubMed ID: 37667452
[TBL] [Abstract][Full Text] [Related]
23. Structural basis for benzothiazinone-mediated killing of Mycobacterium tuberculosis.
Neres J; Pojer F; Molteni E; Chiarelli LR; Dhar N; Boy-Röttger S; Buroni S; Fullam E; Degiacomi G; Lucarelli AP; Read RJ; Zanoni G; Edmondson DE; De Rossi E; Pasca MR; McKinney JD; Dyson PJ; Riccardi G; Mattevi A; Cole ST; Binda C
Sci Transl Med; 2012 Sep; 4(150):150ra121. PubMed ID: 22956199
[TBL] [Abstract][Full Text] [Related]
24. Development of 6-Methanesulfonyl-8-nitrobenzothiazinone Based Antitubercular Agents.
Shi R; Wang B; Stelitano G; Wu X; Shan Y; Wu Y; Wang X; Chiarelli LR; Lu Y; Qiao C
ACS Med Chem Lett; 2022 Apr; 13(4):593-598. PubMed ID: 35450361
[TBL] [Abstract][Full Text] [Related]
25. Scaffold Morphing To Identify Novel DprE1 Inhibitors with Antimycobacterial Activity.
R MM; Shandil R; Panda M; Sadler C; Ambady A; Panduga V; Kumar N; Mahadevaswamy J; Sreenivasaiah M; Narayan A; Guptha S; Sharma S; Sambandamurthy VK; Ramachandran V; Mallya M; Cooper C; Mdluli K; Butler S; Tommasi R; Iyer PS; Narayanan S; Chatterji M; Shirude PS
ACS Med Chem Lett; 2019 Oct; 10(10):1480-1485. PubMed ID: 31620237
[TBL] [Abstract][Full Text] [Related]
26. Virtual Screening of Small Molecular Inhibitors against DprE1.
Zhang G; Guo S; Cui H; Qi J
Molecules; 2018 Feb; 23(3):. PubMed ID: 29495447
[TBL] [Abstract][Full Text] [Related]
27. Drug distribution and efficacy of the DprE1 inhibitor BTZ-043 in the C3HeB/FeJ mouse tuberculosis model.
Ramey ME; Kaya F; Bauman AA; Massoudi LM; Sarathy JP; Zimmerman MD; Scott DWL; Job AM; Miller-Dawson JA; Podell BK; Lyons MA; Dartois V; Lenaerts AJ; Robertson GT
Antimicrob Agents Chemother; 2023 Nov; 67(11):e0059723. PubMed ID: 37791784
[TBL] [Abstract][Full Text] [Related]
28. Optimization of Hydantoins as Potent Antimycobacterial Decaprenylphosphoryl-β-d-Ribose Oxidase (DprE1) Inhibitors.
Balabon O; Pitta E; Rogacki MK; Meiler E; Casanueva R; Guijarro L; Huss S; Lopez-Roman EM; Santos-Villarejo Á; Augustyns K; Ballell L; Aguirre DB; Bates RH; Cunningham F; Cacho M; Van der Veken P
J Med Chem; 2020 May; 63(10):5367-5386. PubMed ID: 32342688
[TBL] [Abstract][Full Text] [Related]
29. Discovery of Novel Thiophene-arylamide Derivatives as DprE1 Inhibitors with Potent Antimycobacterial Activities.
Wang P; Batt SM; Wang B; Fu L; Qin R; Lu Y; Li G; Besra GS; Huang H
J Med Chem; 2021 May; 64(9):6241-6261. PubMed ID: 33852302
[TBL] [Abstract][Full Text] [Related]
30. Decaprenylphosphoryl-β-D-ribose 2'-epimerase, the target of benzothiazinones and dinitrobenzamides, is an essential enzyme in Mycobacterium smegmatis.
Crellin PK; Brammananth R; Coppel RL
PLoS One; 2011 Feb; 6(2):e16869. PubMed ID: 21346818
[TBL] [Abstract][Full Text] [Related]
31. Towards a new combination therapy for tuberculosis with next generation benzothiazinones.
Makarov V; Lechartier B; Zhang M; Neres J; van der Sar AM; Raadsen SA; Hartkoorn RC; Ryabova OB; Vocat A; Decosterd LA; Widmer N; Buclin T; Bitter W; Andries K; Pojer F; Dyson PJ; Cole ST
EMBO Mol Med; 2014 Mar; 6(3):372-83. PubMed ID: 24500695
[TBL] [Abstract][Full Text] [Related]
32. Identification of a Chemical Inhibitor with a Novel Scaffold Targeting Decaprenylphosphoryl-β-D-Ribose Oxidase (DprE1).
Matsunaga T; Monobe K; Aoki S
Infect Disord Drug Targets; 2023; 23(5):e090323214508. PubMed ID: 36892121
[TBL] [Abstract][Full Text] [Related]
33. Structure based pharmacophore modelling approach for the design of azaindole derivatives as DprE1 inhibitors for tuberculosis.
Kb S; Kumari A; Shetty D; Fernandes E; Dv C; Jays J; Murahari M
J Mol Graph Model; 2020 Dec; 101():107718. PubMed ID: 32949960
[TBL] [Abstract][Full Text] [Related]
34. Efficient Synthesis of Benzothiazinone Analogues with Activity against Intracellular Mycobacterium tuberculosis.
Richter A; Narula G; Rudolph I; Seidel RW; Wagner C; Av-Gay Y; Imming P
ChemMedChem; 2022 Mar; 17(6):e202100733. PubMed ID: 34939744
[TBL] [Abstract][Full Text] [Related]
35. Structural basis of inhibition of Mycobacterium tuberculosis DprE1 by benzothiazinone inhibitors.
Batt SM; Jabeen T; Bhowruth V; Quill L; Lund PA; Eggeling L; Alderwick LJ; Fütterer K; Besra GS
Proc Natl Acad Sci U S A; 2012 Jul; 109(28):11354-9. PubMed ID: 22733761
[TBL] [Abstract][Full Text] [Related]
36. 2,6-Disubstituted 7-(naphthalen-2-ylmethyl)-7H-purines as a new class of potent antitubercular agents inhibiting DprE1.
Finger V; Kucera T; Kafkova R; Muckova L; Dolezal R; Kubes J; Novak M; Prchal L; Lakatos L; Andrs M; Hympanova M; Marek J; Kufa M; Spiwok V; Soukup O; Mezeiova E; Janousek J; Nevosadova L; Benkova M; Kitson RRA; Kratky M; Bősze S; Mikusova K; Hartkoorn R; Roh J; Korabecny J
Eur J Med Chem; 2023 Oct; 258():115611. PubMed ID: 37421887
[TBL] [Abstract][Full Text] [Related]
37. Leads for antitubercular compounds from kinase inhibitor library screens.
Magnet S; Hartkoorn RC; Székely R; Pató J; Triccas JA; Schneider P; Szántai-Kis C; Orfi L; Chambon M; Banfi D; Bueno M; Turcatti G; Kéri G; Cole ST
Tuberculosis (Edinb); 2010 Nov; 90(6):354-60. PubMed ID: 20934382
[TBL] [Abstract][Full Text] [Related]
38. Analogous mechanisms of resistance to benzothiazinones and dinitrobenzamides in Mycobacterium smegmatis.
Ribeiro AL; Degiacomi G; Ewann F; Buroni S; Incandela ML; Chiarelli LR; Mori G; Kim J; Contreras-Dominguez M; Park YS; Han SJ; Brodin P; Valentini G; Rizzi M; Riccardi G; Pasca MR
PLoS One; 2011; 6(11):e26675. PubMed ID: 22069462
[TBL] [Abstract][Full Text] [Related]
39. Current Affairs, Future Perspectives of Tuberculosis and Antitubercular Agents.
Gawad J; Bonde C
Indian J Tuberc; 2018 Jan; 65(1):15-22. PubMed ID: 29332642
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and structure-activity relationships evaluation of benzothiazinone derivatives as potential anti-tubercular agents.
Gao C; Ye TH; Wang NY; Zeng XX; Zhang LD; Xiong Y; You XY; Xia Y; Xu Y; Peng CT; Zuo WQ; Wei Y; Yu LT
Bioorg Med Chem Lett; 2013 Sep; 23(17):4919-22. PubMed ID: 23886691
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
